MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study
to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral
sclerosis (ALS)